Oxford BioDynamics (LON:OBD) Stock Price Passes Below 50-Day Moving Average – Time to Sell?

Oxford BioDynamics Plc (LON:OBD – Get Free Report) passed below its 50 day moving average during trading on Wednesday . The stock has a 50 day moving average of GBX 0.14 and traded as low as GBX 0.10. Oxford BioDynamics shares last traded at GBX 0.11, with a volume of 25,940,104 shares traded.

Oxford BioDynamics Price Performance

The company has a market capitalization of £5.15 million, a PE ratio of -0.60 and a beta of 0.42. The company has a debt-to-equity ratio of 131.61, a quick ratio of 2.80 and a current ratio of 2.01. The stock has a 50 day moving average price of GBX 0.14 and a two-hundred day moving average price of GBX 0.20.

Get Oxford BioDynamics alerts:

Oxford BioDynamics (LON:OBD – Get Free Report) last issued its quarterly earnings data on Tuesday, June 30th. The biotechnology company reported GBX (0.10) earnings per share for the quarter. Oxford BioDynamics had a negative net margin of 825.61% and a negative return on equity of 451.74%.

Oxford BioDynamics Company Profile

(Get Free Report)

Oxford BioDynamics Plc is a global biotechnology company, advancing personalized healthcare by developing and commercializing precision medicine tests for life-changing diseases.

Its flagship product is EpiSwitch® CiRT (Checkpoint Inhibitor Response Test) for cancer, a predictive immune response profile for immuno-oncology (IO) checkpoint inhibitor treatments, launched in February 2022.

In March 2021, the Company launched its first commercial prognostic test, EpiSwitch® CST (Covid Severity Test) and the first commercially available microarray kit for high-resolution 3D genome profiling and biomarker discovery, EpiSwitch® Explorer Array Kit.

Recommended Stories

• Five stocks we like better than Oxford BioDynamics
• Datadog’s Drop Says More About Expectations Than Earnings
• D-Wave’s Quantum Breakthrough Couldn’t Save QBTS From a Sell-Off
• Cloudflare’s Beat-and-Raise Quarter Puts Its AI Edge Story in Focus
• Solventum Nears Inflection Point As It Begins to Unlock Value

Receive News & Ratings for Oxford BioDynamics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford BioDynamics and related companies with MarketBeat.com's FREE daily email newsletter.